CLARITEV CORP (CTEV) Fundamental Analysis & Valuation

NYSE:CTEV • US62548M2098

17.21 USD
-0.5 (-2.82%)
At close: Mar 6, 2026
17.21 USD
0 (0%)
After Hours: 3/6/2026, 8:10:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This CTEV fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Overall CTEV gets a fundamental rating of 2 out of 10. We evaluated CTEV against 35 industry peers in the Health Care Technology industry. CTEV has a bad profitability rating. Also its financial health evaluation is rather negative. CTEV has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

3

1. CTEV Profitability Analysis

1.1 Basic Checks

  • In the past year CTEV has reported negative net income.
  • CTEV had a positive operating cash flow in the past year.
  • In the past 5 years CTEV reported 4 times negative net income.
  • Of the past 5 years CTEV 4 years had a positive operating cash flow.
CTEV Yearly Net Income VS EBIT VS OCF VS FCFCTEV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -500M -1B -1.5B

1.2 Ratios

  • CTEV has a Return On Assets of -6.85%. This is in the better half of the industry: CTEV outperforms 65.71% of its industry peers.
  • The Return On Invested Capital of CTEV (0.82%) is better than 62.86% of its industry peers.
  • CTEV had an Average Return On Invested Capital over the past 3 years of 2.41%. This is below the industry average of 7.01%.
Industry RankSector Rank
ROA -6.85%
ROE N/A
ROIC 0.82%
ROA(3y)-13.68%
ROA(5y)-9.22%
ROE(3y)-665.39%
ROE(5y)-402.43%
ROIC(3y)2.41%
ROIC(5y)N/A
CTEV Yearly ROA, ROE, ROICCTEV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

  • With a decent Operating Margin value of 5.21%, CTEV is doing good in the industry, outperforming 71.43% of the companies in the same industry.
  • CTEV's Operating Margin has declined in the last couple of years.
  • With a decent Gross Margin value of 74.72%, CTEV is doing good in the industry, outperforming 74.29% of the companies in the same industry.
  • In the last couple of years the Gross Margin of CTEV has declined.
Industry RankSector Rank
OM 5.21%
PM (TTM) N/A
GM 74.72%
OM growth 3Y-33.57%
OM growth 5Y-22.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.14%
GM growth 5Y-2.61%
CTEV Yearly Profit, Operating, Gross MarginsCTEV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. CTEV Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CTEV is destroying value.
  • There is no outstanding debt for CTEV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CTEV Yearly Shares OutstandingCTEV Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 200M 400M 600M
CTEV Yearly Total Debt VS Total AssetsCTEV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.2 Solvency

  • CTEV has an Altman-Z score of -0.39. This is a bad value and indicates that CTEV is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of CTEV (-0.39) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -0.39
ROIC/WACC0.13
WACC6.1%
CTEV Yearly LT Debt VS Equity VS FCFCTEV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B 5B

2.3 Liquidity

  • CTEV has a Current Ratio of 1.21. This is a normal value and indicates that CTEV is financially healthy and should not expect problems in meeting its short term obligations.
  • CTEV's Current ratio of 1.21 is on the low side compared to the rest of the industry. CTEV is outperformed by 74.29% of its industry peers.
  • CTEV has a Quick Ratio of 1.21. This is a normal value and indicates that CTEV is financially healthy and should not expect problems in meeting its short term obligations.
  • CTEV has a worse Quick ratio (1.21) than 68.57% of its industry peers.
Industry RankSector Rank
Current Ratio 1.21
Quick Ratio 1.21
CTEV Yearly Current Assets VS Current LiabilitesCTEV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. CTEV Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 75.83% over the past year.
EPS 1Y (TTM)75.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%6.21%

3.2 Future

  • Based on estimates for the next years, CTEV will show a small growth in Earnings Per Share. The EPS will grow by 6.45% on average per year.
  • The Revenue is expected to grow by 3.99% on average over the next years.
EPS Next Y13.61%
EPS Next 2Y11.67%
EPS Next 3Y6.45%
EPS Next 5YN/A
Revenue Next Year3.06%
Revenue Next 2Y3.81%
Revenue Next 3Y3.99%
Revenue Next 5YN/A

3.3 Evolution

CTEV Yearly Revenue VS EstimatesCTEV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 200M 400M 600M 800M 1B
CTEV Yearly EPS VS EstimatesCTEV Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -20 -40 -60 -80

More info and screens

Find the best growth stocksShow best growing peers

1

4. CTEV Valuation Analysis

4.1 Price/Earnings Ratio

  • CTEV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year CTEV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CTEV Price Earnings VS Forward Price EarningsCTEV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

  • CTEV's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. CTEV is cheaper than 82.86% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 9.91
CTEV Per share dataCTEV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -100 -200

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.67%
EPS Next 3Y6.45%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CTEV Dividend Analysis

5.1 Amount

  • CTEV does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CTEV Fundamentals: All Metrics, Ratios and Statistics

CLARITEV CORP

NYSE:CTEV (3/6/2026, 8:10:01 PM)

After market: 17.21 0 (0%)

17.21

-0.5 (-2.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)02-23
Earnings (Next)05-06
Inst Owners56.22%
Inst Owner ChangeN/A
Ins Owners6.58%
Ins Owner Change32.89%
Market Cap284.83M
Revenue(TTM)N/A
Net Income(TTM)-341.68M
Analysts83.64
Price Target66.1 (284.08%)
Short Float %10.56%
Short Ratio3.96
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.42%
Min EPS beat(2)-15.41%
Max EPS beat(2)2.57%
EPS beat(4)2
Avg EPS beat(4)-5.44%
Min EPS beat(4)-23.58%
Max EPS beat(4)14.65%
EPS beat(8)4
Avg EPS beat(8)-188.45%
EPS beat(12)6
Avg EPS beat(12)-288.48%
EPS beat(16)7
Avg EPS beat(16)-215.53%
Revenue beat(2)2
Avg Revenue beat(2)2.38%
Min Revenue beat(2)2.26%
Max Revenue beat(2)2.51%
Revenue beat(4)3
Avg Revenue beat(4)0.94%
Min Revenue beat(4)-2.88%
Max Revenue beat(4)2.51%
Revenue beat(8)3
Avg Revenue beat(8)-1.92%
Revenue beat(12)5
Avg Revenue beat(12)-1.32%
Revenue beat(16)7
Avg Revenue beat(16)-1.84%
PT rev (1m)0%
PT rev (3m)-26.64%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.38%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.04%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.06%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.3
P/FCF N/A
P/OCF 16.13
P/B N/A
P/tB N/A
EV/EBITDA 9.91
EPS(TTM)-16.82
EYN/A
EPS(NY)-14.53
Fwd EYN/A
FCF(TTM)-6.78
FCFYN/A
OCF(TTM)1.07
OCFY6.2%
SpS57.46
BVpS-6.15
TBVpS-270.29
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -6.85%
ROE N/A
ROCE 1.04%
ROIC 0.82%
ROICexc 0.83%
ROICexgc 10.68%
OM 5.21%
PM (TTM) N/A
GM 74.72%
FCFM N/A
ROA(3y)-13.68%
ROA(5y)-9.22%
ROE(3y)-665.39%
ROE(5y)-402.43%
ROIC(3y)2.41%
ROIC(5y)N/A
ROICexc(3y)2.48%
ROICexc(5y)N/A
ROICexgc(3y)66.67%
ROICexgc(5y)N/A
ROCE(3y)3.05%
ROCE(5y)N/A
ROICexgc growth 3Y-40.96%
ROICexgc growth 5Y-27.14%
ROICexc growth 3Y-26.84%
ROICexc growth 5Y-14.89%
OM growth 3Y-33.57%
OM growth 5Y-22.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.14%
GM growth 5Y-2.61%
F-Score6
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 9.38
Cap/Depr 29.31%
Cap/Sales 13.65%
Interest Coverage 0.14
Cash Conversion 3.59%
Profit Quality N/A
Current Ratio 1.21
Quick Ratio 1.21
Altman-Z -0.39
F-Score6
WACC6.1%
ROIC/WACC0.13
Cap/Depr(3y)25.06%
Cap/Depr(5y)22.79%
Cap/Sales(3y)10.77%
Cap/Sales(5y)9.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)75.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
EPS Next Y13.61%
EPS Next 2Y11.67%
EPS Next 3Y6.45%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%6.21%
Revenue Next Year3.06%
Revenue Next 2Y3.81%
Revenue Next 3Y3.99%
Revenue Next 5YN/A
EBIT growth 1Y-61.12%
EBIT growth 3Y-37.5%
EBIT growth 5Y-23.25%
EBIT Next Year145.66%
EBIT Next 3Y35.43%
EBIT Next 5Y25.74%
FCF growth 1Y-263.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-89.72%
OCF growth 3Y-35.69%
OCF growth 5Y-17.66%

CLARITEV CORP / CTEV FAQ

Can you provide the ChartMill fundamental rating for CLARITEV CORP?

ChartMill assigns a fundamental rating of 2 / 10 to CTEV.


What is the valuation status of CLARITEV CORP (CTEV) stock?

ChartMill assigns a valuation rating of 1 / 10 to CLARITEV CORP (CTEV). This can be considered as Overvalued.


What is the profitability of CTEV stock?

CLARITEV CORP (CTEV) has a profitability rating of 3 / 10.


What is the earnings growth outlook for CLARITEV CORP?

The Earnings per Share (EPS) of CLARITEV CORP (CTEV) is expected to grow by 13.61% in the next year.